National Anti-Drug Strategy Evaluation

Appendix B: List of Evaluation Issues and Questions

List of Evaluation Issues and Questions
Categories Evaluation Issues and Questions
Relevance
  1. Is there a continued need for the National Anti-Drug Strategy?
  2. To what extent are the objectives and priorities of the Strategy still relevant in relation to federal priorities concerning illicit drug use?
  3. Does the Strategy align with federal roles and responsibilities in this program area?
Effectiveness
  1. To what extent has the Prevention Action Plan achieved its immediate outcomes?
    • Supporting efforts to increase awareness and understanding of illicit drugs and their negative consequences
    • Developing enhanced supports for targeted/at risk populations
    • Contributing to enhanced community uptake of knowledge about how to address illicit drug use and its negative consequences
  2. To what extent has the Prevention Action Plan achieved its intermediate outcomes?
    • Enhancing capacity of targeted populations to make informed decisions about illicit drug use
    • Strengthening community responses to illicit drug issues in targeted areas
    • Reducing risk-taking behaviour among targeted groups
  3. To what extend has the Treatment Action Plan achieved its immediate outcomes?
    • Enhanced capacity to plan/deliver a range of treatment services and programs to targeted populations
    • Improved collaboration on responses and knowledge of treatment issues
    • Enhanced federal-provincial/territorial commitments to improve treatment systems in targeted areas of need
  4. To what extent has the Treatment Action Plan achieved its intermediate outcomes?
    • Increased availability of and access to effective treatment services and programs for targeted populations in areas of need
    • Improving treatment systems, programs and services to address illicit drug dependency in targeted population in areas of need
    • Reducing risk-taking behaviours
  5. To what extent has the Enforcement Action Plan achieved its immediate outcomes?
    • Increased capacity for drug enforcement and prosecution of illicit drug producers and distributors
    • Increased capacity to gather, analyze and share intelligence and analyze evidence
    • Increased awareness of illicit drug and precursor chemicals issues for enforcement officials
    • Increased capacity to control and monitor controlled substances and precursor chemicals
  6. To what extent has the Enforcement Action Plan achieved its intermediate outcomes?
    • Increased/enhanced investigations, audits, charges, forensic accounting analyses and prosecutions
    • Improved intelligence and evidence
    • Increased safety in dismantling illicit drug operations
    • Increased compliance/seizures and reduced risk/occurrence of diversion of precursor chemicals
    • Increased dismantling/disruption of organizations/operations related to illicit drug production and distribution
    • Reduced health, safety and security risks associated with illicit drug production, seizure and dismantling operations
  7. Are there any unintended impacts, problems or gaps that have resulted from the implementation of the Strategy?
Efficiency and Economy
  1. How cost-efficient is the Strategy (components of the prevention and treatment action plans, overall Strategy lead function)?
  2. Does the Strategy represent the most appropriate mix of policies, programs and services for the federal government to contribute to the prevention of illicit drug use, treatment of dependency and reduction in the production and distribution of illicit drug crime?
  3. To what extent is the way in which the Strategy is being managed (horizontal initiative) likely to support the achievement of its objectives?
  4. Are there sufficient resources to manage the Strategy?
  5. Are there better ways of accomplishing the Strategy’s objectives?